Relay Therapeutics Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 12.51, 16.02, 33.61, 186.63, 466.61 ], "ebit_estimate": [ -307.89, -320.96, -306.76, -239.73, -44.95 ], "ebitda_estimate": [ -313.3, -317.07, -334.76, -175.06, -28.01 ], "net_income_estimate": [ -290.96, -301.82, -324.86, -225.63, -38.54 ], "per_share_eps_estimate": [ -1.56, -1.62, -1.56, -1.05, -0.16 ], "eps_nri_estimate": [ -1.56, -1.59, -1.57, -1.05, -0.16 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 3.63, 1.91, 1.48, null, null ], "pretax_income_estimate": [ -228.61, -308.2, -317.17, -203.07, -2.13 ], "operating_cash_flow_per_share_estimate": [ -1.37, -1.32, -1.24, null, null ], "roa_estimate": [ -45.8, -57.7, -75.6, null, null ], "roe_estimate": [ -61.39, -64.4, -89, null, null ], "gross_margin_estimate": [ 100, 100, 97.5, 79, 82.5 ], "operating_cash_flow_estimate": [ -245.49, -236.5, -223.01, null, null ], "pettm_estimate": [ 0, 0, 0, 0, 0 ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "29.67", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": 29.67, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": -3.55, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -5.34, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": -26.01, "future_roa_estimate_growth": -26.75, "future_roe_estimate_growth": -26.67, "future_gross_margin_estimate_growth": -0.76, "future_operating_cash_flow_per_share_estimate_growth": 3.31 }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712", "202803" ], "revenue_estimate": [ 0.87, 1.96, 6.83, 0.05, null, null, null, null ], "ebit_estimate": [ -77.85, -78.61, -74.57, -79.91, -78.12, -79.35, -80.61, -84.31 ], "ebitda_estimate": [ -78.64, -80.33, -74.85, -79.64, -77.4, -78.81, -79.87, -83.95 ], "net_income_estimate": [ -73.87, -74.75, -69.74, -76.92, -78.12, -79.35, -80.61, -84.31 ], "per_share_eps_estimate": [ -0.4, -0.39, -0.36, -0.39, -0.39, -0.39, -0.38, -0.38 ], "eps_nri_estimate": [ -0.39, -0.39, -0.36, -0.39, -0.39, -0.39, -0.38, -0.38 ], "dividend_estimate": [ null, null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null, null ], "pretax_income_estimate": [ -73.33, -73.88, -65.76, -76.92, -78.12, -79.35, -80.61, -84.31 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null, null ], "gross_margin_estimate": [ 100, 100, 100, 100, 100, 100, 100, 100 ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, 0, null, null, null ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "29.67", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": 29.67, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": -3.55, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -5.34, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": -26.01, "future_roa_estimate_growth": -26.75, "future_roe_estimate_growth": -26.67, "future_gross_margin_estimate_growth": -0.76, "future_operating_cash_flow_per_share_estimate_growth": 3.31 }